Wide-Spread Clinical
Evidence using the MolecuLight Imaging
Platform Reveals its Significant Global Adoption and Proven
Utility in Wound Care
TORONTO and LONDON, May 1,
2024 /PRNewswire/ -- MolecuLight Inc., the leader in
point-of-care digital wound measurement and real-time bacterial
detection through fluorescence imaging, announces that its
MolecuLight wound imaging platform is being prominently featured in
several presentations and posters at the European Wound Management
Association (EWMA) 2024 Annual Conference, being held from
May 1 - 3, 2024 in London, United Kingdom. The annual EWMA
meeting is the largest wound care conference in Europe and one of the largest events globally
for wound care professionals.
"We are humbled by the widespread adoption of MolecuLight
point-of-care devices among clinicians worldwide who see it as an
invaluable and transformative tool in their wound care practices",
says Anil Amlani, MolecuLight's CEO. "The impressive collection of
at least 11 talks and posters from multiple and diverse facilities
globally shows how the MolecuLight imaging device is becoming a new
standard-of-care in this specialty. The diverse array of presenters
from North America, Europe, and South
America underscores the global reach of the MolecuLight
imaging technology. The clinical evidence showing at EWMA is echoed
in the 80+ peer-reviewed publications which span the globe,
showing the significant benefit of the MolecuLight
i:X® and DX™ to clinical wound
assessment, practice, and outcomes."
Dr. Jonathan Johnson, a wound
care thought leader and health equity expert based in Washington, DC, will speak at EWMA on how
MolecuLight's groundbreaking technology overcomes disparities in
wound assessment on dark skin tones. "It's critical to spotlight
the healthcare obstacles disproportionately impacting minority
populations," he says, "and EWMA provides the perfect forum to
reach a global audience with this vital work." When asked about his
upcoming presentation, Dr. Johnson shares, "I'm honored to share my
latest research showing how MolecuLight enhances bacterial
detection in wounds regardless of skin tone, a critical limitation
of traditional clinical assessment. This technology is helping
break down significant barriers to equitable care. By supporting
the adoption of MolecuLight imaging, we are paving the way for a
healthier, fairer future."
"As the lead author of two studies to be presented at this
iteration of EWMA featuring MolecuLight, I am thrilled to showcase
how fluorescence signals can revolutionize bacterial management,
ultimately leading to optimized wound outcomes", says Rosemarie Derwin, an experienced nurse,
educator, and researcher from Dublin,
Ireland, "Our research underscores how essential adequate
and objective bacterial removal from the wound bed is in our
efforts to achieve healing, and ultimately improve our patients'
quality of life", she concludes.
The collection of 4 presentations and 7 posters featuring the
MolecuLight imaging devices show how clinical decision-making is
informed and enhanced through its digital wound measurement
feature, detection of high bacterial burden in wounds at the
bedside, and, remarkably, its ability to monitor and track wound
size and bioburden over time while minimizing operator bias.
Presented studies span the wound care continuum, including:
- Accuracy of MolecuLight across all skin pigmentations and
chronic wound types,
- Detection of biofilm with MolecuLight,
- Wound area reduction achieved by removing fluorescence
signals,
- Combined use of thermal and fluorescence imaging in a single
MolecuLight device,
- Novel diagnostic approaches using MolecuLight to treat pyoderma
gangrenosum, and
- Enhanced patient adherence and engagement.
The findings that will
be presented illustrate the significant clinical
improvements to multiple aspects of wound care
provided by the MolecuLight platform.
A selection
of the clinical posters and presentation featuring
the MolecuLight i:X and
DX from European Wound Management Association (EWMA)
2024 Annual Conference are as follows:
(a) Select Clinical Presentations and
Workshops
citing the MolecuLight point-of-care devices include:
- Workshop: Painting Wounds on the Skin for Education
Purposes
Workshop including MolecuLight by Astrid Probst
Wednesday May 1st, 17:15 –
18:45 BST, South Gallery 18-19
- Integrating Point-of-Care Bacterial Fluorescence Imaging and
targeted debridement with Continued Wound Measurement for Enhanced
Wound Area Reduction Monitoring
Presentation on MolecuLight
by Rosemarie Derwin
Thursday May 2nd, 17:50 –
17:58 BST, South Gallery 17
- The Impact of High Skin Pigmentation on the Clinical
Diagnosis of Wound Infection and the Ability to Enhance Diagnosis
with Fluorescence Imaging of Bacteria
Presentation on
MolecuLight by Dr. Jonathan
Johnson
Friday May 3rd, 8:50 –
8:58 BST, South Gallery 11-12
- Does bacterial fluorescence imaging improve chronic wound
biofilm detection over standard clinical assessment and
blotting?
Presentation on MolecuLight by Laura Jones-Donaldson
Friday May 3rd, 8:50 –
8:58 BST, South Gallery 22
- Agreement of microbiological identification by aspiration
puncture versus biopsy guided by bacterial fluorescence in the
diagnosis of complex wound infection
Presentation on
MolecuLight by Carol Serna González
Friday May 3rd, 11:05 –
11:13 BST, South Gallery 22
(b) Select Clinical Posters
citing the MolecuLight point-of-care devices include:
- EP064 Advanced wound care of pyoderma gangrenosum through
fluorescence imaging guided debridement
Charles Andersen, USA
Wednesday May 1st, 11:45 –
13:30 E-POSTER SCREEN 3, SURGICAL APPROACHES
- EP043 Audit of antimicrobial prescribing trends in 1447
outpatient wound assessments: Baseline rates and impact of
bacterial fluorescence imaging
Thomas Serena, USA
Wednesday May 1st, 11:45 –
13:30 BST, E-POSTER SCREEN 2,
ANTIMICROBIALS
- EP217 Empowering patients through fluorescence imaging: key
insights for advancing wound care success from survey
results
Charles
Andersen, USA
Thursday May 2nd, 10:00 –
11:15 BST, E-POSTER SCREEN 3,
EDUCATION
- EP345 The clinical utility of auto-fluorescence imaging in
detecting the presence of bacteria in wounds - a systematic
review
Rosemarie
Derwin, Ireland
Thursday May 2nd, 17:00 –
18:30 BST, E-POSTER SCREEN 3, WOUND
ASSESSMENT
- EP416 Multimodal imaging device for real time bacterial load
and thermal imaging: A study of synergy in clinical wound
assessment workflow
Charles
Andersen, USA
Friday May
3rd, 12:45 – 13:30
BST, E-POSTER SCREEN 3, DEVICES & INTERVENTION 2
- EP540 Fifty shades of red
fluorescence
Laura
Jones-Donaldson, Canada
DISPLAY ONLY, E-POSTER BROWSING
STATIONS
- EP698 Using auto-fluorescence imaging to aid early diagnosis
of wound infection in a patient with dark skin tone
Nadine Price, UK
DISPLAY
ONLY, E-POSTER BROWSING STATIONS
The MolecuLight i:X and DX are the
only imaging devices for the real-time detection of elevated
bacterial burden in wounds that are class II FDA-cleared, CE-Marked
and approved by Health Canada. With clinical
evidence including over 80 peer-reviewed publications, the devices are used by leading wound
care facilities globally.
About MolecuLight Inc.
MolecuLight Inc. is a privately owned medical imaging company
with global presence that offers fully commercialized point-of-care
digital wound measurement and real-time bacterial detection through
fluorescence imaging platform technology.
MolecuLight's suite of commercial devices,
which include the MolecuLight i:X® and
DX™ fluorescence imaging and digital wounds measurement
systems and their accessories, have scientifically proven
capabilities that enhance wound care practices and outcomes across
all places of service. MolecuLight procedures performed in
the United States benefit from an
available reimbursement pathway which includes two CPT®
codes for physician work to perform "fluorescence
imaging for bacterial presence
location, and load" and
facility payment for Hospital Outpatient Department (HOPD)
and Ambulatory Surgical Center (ASC) settings through an Ambulatory
Payment Classification (APC) assignment.
CONTACT: Laura Jones-Donaldson, MolecuLight Inc.,
ljones@moleculight.com, T. +1.416.542.5507,
www.moleculight.com
Photo -
https://mma.prnewswire.com/media/2400710/MolecuLight_MolecuLight_Featured_in_11_Presentations_and_Posters.jpg
Logo -
https://mma.prnewswire.com/media/2400709/MolecuLight_MolecuLight_Featured_in_11_Presentations_and_Posters.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/moleculight-featured-in-11-presentations-and-posters-at-european-wound-management-association-ewma-2024-annual-conference-302130744.html